In a Phase IIb, dose-finding, randomised, placebo-controlled trial (SYNERGY-NASH) involving 190 participants with obesity and biopsy-confirmed MASH and stage F2 or F3 fibrosis, once-weekly subcutaneous tirzepatide (5 mg, 10 mg or 15 mg for 52 weeks) resulted in significantly higher rates of MASH resolution without worsening of fibrosis (44%, 56% and 62%, respectively) than placebo (10%)
Wegovy Injections (semaglutide) is a single-receptor agonist it acts on the GLP-1 receptor alone
Early identification and treatment are necessary to prevent disease progression and its associated morbidity and mortality
Therefore, GLP-1RAs hold promise as a novel therapeutic approach for diabetic patients with reduced -cell mass, stimulating -cell proliferation and differentiation (Iqbal et al., 2021)
H2 Blockers: Medications like famotidine (Pepcid) work differently than PPIs and might be more effective for some individuals